Infliximab, azathioprine or combination therapy in the treatment of active Crohns disease

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 6, 2010, Pages 709-712

  Cottone, Mario ^a   Papi, Claudio ^b   Orlando, Ambrogio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

active Crohns disease; azathioprine; combination therapy; infliximab

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; MESALAZINE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NOTE; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION;

EID: 78649674617     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.68     Document Type: Note

References (15)

1. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for infammatory bowel disease: a population-based study. Gastroenterology 121, 255-260 (2001).
2. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann. Intern. Med. 123, 132-142 (1995).
3. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst. Rev. 2, CD000067 (2000).
4. Targan SR, Hanauer SB, van Deventer SJ et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. Crohn's Disease cA2 study group. N. Engl. J. Med. 337, 1029-1035 (1997).
5. Hanauer SB, Feagan BG, Lichtenstein G et al.; for the ACCENT 1 Study Group. Maintenance infiximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002).
6. Lémann M, Mary JY, Duclos B et al. Infiximab plus azathioprine for steroid dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130, 1054-1061 (2006).
7. Colombel JF, Sandborn W, Reinish W et al.; for the SONIC Study Group. Infiximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010).
8. Fraser AG, Orchard TR, Jewell DP. The effcacy of azathioprine for the treatment of infammatory bowel disease: a 30 year review. Gut 50, 485-489 (2002).
9. Ewe K, Press AG, Singe CC et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 105, 367-372 (1993).
10. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 2, 944-947 (1971).
11. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37, 674-678 (1995).
12. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N. Engl. J. Med. 302, 981-987 (1980). (Pubitemid 10125406)
13. Summers RW, Switz DM, Sessions JT Jr et al. National Cooperative Crohn's disease study: results of drug treatment. Gastroenterology 77, 847-869 (1979).
14. Reinisch W, Panes J, Lémannn M et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to severe active Crohn's disease. Am. J. Gastroenterol. 103, 2284-2292 (2008).
15. Cottone M, Kohn A, Daperno M et al. Age is a risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for infammatory bowel disease. Clin. Gastroenterol. Hepatol. DOI: 10.1016/j.cgh.2010.09.026 (2010) (Epub ahead of print).